secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001193125-25-110696
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma and ALK co-promote neffy nasal spray to up to 9,000 U.S. pediatricians
--------------------------------------------------------------------------------

- Co-promotion agreement with ALK-Abelló, Inc. for neffy (epinephrine nasal spray) targeting pediatricians and other prescribers.
- ALK starts promotion activities May 2025, must meet ramp-up milestones and minimum detail requirements; non-compete on injectable epinephrine.
- ARS books all U.S. sales; ALK receives base fee (first-year deferred) and performance bonuses from year 2: 30% of net sales above preset market share thresholds.
- Agreement expires after 4 years; termination provisions include for convenience (with fee) and change of control (mid-seven to low eight-digit fee).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525110696/0001193125-25-110696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525110696/d26679d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-110696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer